Janssen Submits EU Marketing Application for VELCADE® (bortezomib) in Mantle Cell Lymphoma

  Janssen Submits EU Marketing Application for VELCADE® (bortezomib) in Mantle
  Cell Lymphoma

Type II variation submitted to the European Medicines Agency to expand current
   VELCADE® label to include previously untreated patients with Mantle Cell
                                   Lymphoma

Business Wire

BEERSE, Belgium -- June 27, 2014

Janssen-Cilag International NV today announced its submission of a type II
variation to the European Medicines Agency (EMA) to expand the label for
VELCADE® (bortezomib) to include its use, in combination with rituximab,
cyclophosphamide, doxorubicin and prednisone, for the treatment of adult
patients with previously untreated Mantle Cell Lymphoma (MCL). MCL is a rare
and aggressive blood cancer that usually occurs in older adults.^1 VELCADE, in
combination with other agents, is currently licensed to treat patients with
Multiple Myeloma who have not yet had therapy or whose cancer has begun to
progress after treatment.^2

“We are committed to developing and delivering innovative therapeutic
solutions to treat serious diseases,” said Jane Griffiths, Company Group
Chairman, Janssen Europe, the Middle East and Africa (EMEA). “The encouraging
data we have seen on VELCADE when used as part of frontline treatment of
Mantle Cell Lymphoma reinforce our belief that this therapy has the potential
to be an important option in the treatment of this cancer.”

Today’s submission is based on data from the landmark LYM-3002 trial. In
results from this study, presented at the 50^th Annual Meeting of the American
Society of Clinical Oncology (ASCO) and the 19^th Annual Congress of the
European Hematology Association (EHA), significant benefits were seen when
treating newly diagnosed patients with MCL using a VELCADE-based combination,
compared to a widely used standard of care. Patients in the study were
previously untreated for their MCL and were either ineligible, or not
considered, for a bone marrow transplant. Compared to the treatment
combination R-CHOP^†, the VELCADE-based regimen, VR-CAP^* significantly
improved progression-free survival (PFS) (the time patients live without their
disease progressing) and showed improvements across a range of secondary
endpoints.^3 An independent review committee reported the increase in median
PFS to be 59 percent (24.7 vs. 14.4 months; HR 0.63; p<0.001), whereas the
study investigators reported the increase in median PFS to be 96 percent (30.7
vs. 16.1 months; HR 0.51; p<0.001).^3

VR-CAP was associated with additional, but manageable, toxicity as compared to
R-CHOP.^3 Higher rates of thrombocytopenia and infection were observed with
VR-CAP. However, there were no differences observed in bleeding events between
the two treatment groups and rates of peripheral neuropathy were similar.^3
Overall, among patients receiving VR-CAP compared to R-CHOP in the LYM 3002
study, serious adverse events (AE) were reported in 38 percent vs. 30 percent
of patients and grade ≥3 AEs were reported in 93 percent vs. 85 percent.
Discontinuations of treatment due to AEs were nine percent (VR-CAP) vs. seven
percent (R-CHOP) and on-treatment drug-related deaths were two percent vs.
three percent.^3

                                   # ENDS #

Notes to editors

About VELCADE (bortezomib)

VELCADE (bortezomib) is a medicine currently licensed in the EU to treat the
blood-based cancer, Multiple Myeloma (MM). VELCADE is currently indicated for
use in the following groups:^2

  *Patients who have not been treated before and who are not suitable for
    high-dose chemotherapy (medicines to treat cancer) with a blood stem-cell
    transplant. In these patients, VELCADE is used in combination with
    melphalan and prednisone (other medicines for MM)
  *Patients who have not been treated before and who are going to receive
    high-dose chemotherapy followed by a blood stem-cell transplant. In this
    group of patients, VELCADE is used in combination with dexamethasone, or
    with dexamethasone plus thalidomide
  *Patients whose disease is progressive (getting worse) and who have failed
    to respond to at least one other treatment and have already had, or cannot
    undergo, a blood stem-cell transplant. VELCADE is either used on its own
    in these patients or in combination with CAELYX (pegylated liposomal
    doxorubicin) or dexamethasone

VELCADE contains an active substance called bortezomib and is the first in a
specific class of medicines known as proteasome inhibitors. Proteasomes are
present in all cells and play an important role in controlling cell function,
growth and also how cells interact with other cells around them. Bortezomib
reversibly interrupts the normal working of cell proteasomes, causing myeloma
cancer cells to stop growing and die.^2

VELCADE has a predictable safety profile and a favourable benefit–risk ratio.
The most common side effects reported with VELCADE (bortezomib) ^ include
fatigue, gastrointestinal adverse events, transient thrombocytopenia and
neuropathy.^2

VELCADE is the market leader in the treatment of frontline, non-transplant
eligible MM. It is co-developed by Millennium: The Takeda Oncology Company, a
wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Janssen
Pharmaceutical Companies. Millennium: The Takeda Oncology Company is
responsible for commercialisation of VELCADE in the U.S.; Janssen
Pharmaceutical Companies are responsible for commercialisation in Europe and
the rest of the world. Takeda Pharmaceutical Company Limited and Janssen
Pharmaceutical K.K. co-promote VELCADE in Japan. VELCADE is approved in more
than 90 countries and has been used to treat more than 550,000 patients
worldwide.

VELCADE (bortezomib) in Mantle Cell Lymphoma

In Europe, VELCADE is not currently licensed to treat Mantle Cell Lymphoma
(MCL). The approved VELCADE indications can be viewed online at:^2
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000539/human_med_001130.jsp&mid=WC0b01ac058001d124

In 2006, the United States Food and Drug Administration (FDA) approved VELCADE
for the treatment of patients with MCL who have received at least one prior
therapy. VELCADE has subsequently been approved for the treatment of relapsed
MCL in 53 additional countries, including Canada and Switzerland.

About Mantle Cell Lymphoma

MCL is a rare and aggressive blood cancer that usually occurs in older adults,
with the median age at diagnosis being 65 years. The disease typically begins
in the lymph nodes, but can spread to other tissues such as bone marrow, liver
and spleen. The incidence rates among men and women in Europe are
approximately 0.64 and 0.27 cases per 100,000 persons per year, respectively.
MCL patients generally have a poor prognosis. Median overall survival is
typically three to four years, and only one to two years in patients following
the first relapse.^4,5,6

About Janssen

Janssen-Cilag International NV is one of the Janssen Pharmaceutical Companies.
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to
addressing and solving the most important unmet medical needs of our time,
including oncology (e.g. Multiple Myeloma and prostate cancer), immunology
(e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain),
infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and
cardiovascular and metabolic diseases (e.g. diabetes). Driven by our
commitment to patients, we develop sustainable, integrated healthcare
solutions by working side-by-side with healthcare stakeholders, based on
partnerships of trust and transparency. More information can be found on
www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest
news.

Janssen in Oncology

In oncology, our goal is to fundamentally alter the way cancer is understood,
diagnosed, and managed, reinforcing our commitment to the patients who inspire
us. In looking to find innovative ways to address the cancer challenge, our
primary efforts focus on several treatment and prevention solutions. These
include disease area strongholds that focus on haematologic malignancies and
prostate cancer; cancer interception with the goal of developing products that
interrupt the carcinogenic process; biomarkers that may help guide targeted,
individualised use of our therapies; and safe and effective identification and
treatment of early changes in the tumour microenvironment.

This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995 regarding product
development. The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections of Janssen-Cilag International NV, any of the
other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and
uncertainties include, but are not limited to: challenges inherent in new
product development, including obtaining regulatory approvals; competition,
including technological advances, new products and patents attained by
competitors; challenges to patents; changes in behavior and spending patterns
or financial distress of purchasers of health care products and services;
changes to governmental laws and regulations and domestic and foreign health
care reforms; general industry conditions including trends toward health care
cost containment; and increased scrutiny of the health care industry by
government agencies. A further list and description of these risks,
uncertainties and other factors can be found in Johnson & Johnson’s Annual
Report on Form 10-K for the fiscal year ended December 29, 2013, including in
Exhibit 99 thereto, and subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. None of the Janssen
Pharmaceutical Companies or Johnson & Johnson undertakes to update any
forward-looking statements as a result of new information or future events or
developments.

                                     ###

^† Rituximab, cyclophosphamide, doxorubicin, vinicristine and prednisone
(R-CHOP)

^*VELCADE, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP)

REFERENCES

1. Lymphoma Research Foundation: Mantle Cell Lymphoma. Key facts available at
http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300157. Accessed June
2014.
2. VELCADE European Public Assessment Report (EPAR). Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000539/human_med_001130.jsp&mid=WC0b01ac058001d124.
Accessed June, 2014.
3. Cavalli et al. Randomized Phase 3 study of rituximab, cyclophosphamide,
doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP)
in newly diagnosed Mantle Cell Lymphoma (MCL) patients (pts) ineligible for
bone marrow transplantation (BMT). ASCO 2014 Abstract #8500.
4. McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and
management of Mantle Cell Lymphoma. Br J Haematol (2012);159:405-26.
5. Smedby KE, Hjalgrim H. Epidemiology and etiology of Mantle Cell Lymphoma
and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol (2011);21:293-8.
6. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed
or refractory Mantle Cell Lymphoma: updated time-to-event analyses of the
multicenter phase 2 PINNACLE study. Ann Oncol (2009);20:520-5.

Contact:

Janssen-Cilag International NV
Media Inquiries:
Satu Kaarina Glawe, Mobile: +49 (172) 294 6264
or
Investor Relations:
Stan Panasewicz, +1-732-524-2524
Louise Mehrotra, +1-732-524-6491
 
Press spacebar to pause and continue. Press esc to stop.